Get the Stockscreener App
5.985
5.67%
-0.36
Abeona Therapeutics Inc stock is traded at $5.985, with a volume of 5.44M.
It is down -5.67% in the last 24 hours and down -15.23% over the past month.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
See More
Previous Close:
$6.345
Open:
$6.21
24h Volume:
5.44M
Relative Volume:
3.96
Market Cap:
$341.12M
Revenue:
$5.82M
Net Income/Loss:
$71.18M
P/E Ratio:
6.0018
EPS:
0.9972
Net Cash Flow:
$-84.30M
1W Performance:
-17.33%
1M Performance:
-15.23%
6M Performance:
+19.46%
1Y Performance:
-17.22%
1-Day Range:
$5.82
$6.29
1-Week Range:
$5.82
$7.65
52-Week Range:
$4.00
$7.65
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.985 | 425.18M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Montanova Capital (ABEO) reports 0.9% beneficial stake in Abeona Therapeutics - Stock Titan
ABEO Maintained by Oppenheimer -- Price Target Lowered to $21.00 - GuruFocus
Oppenheimer Adjusts PT on Abeona Therapeutics to $21 From $22, Maintains Outperform Rating - marketscreener.com
Abeona Therapeutics earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity (NASDAQ:ABEO) - Seeking Alpha
Abeona Therapeutics (NASDAQ:ABEO) Issues Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
Abeona Therapeutics Shares Fall After Q2 Miss - marketscreener.com
Abeona Therapeutics (ABEO) Advances ZEVASKYN Rollout Amid Mixed Valuation Signals - GuruFocus
Transcript : Abeona Therapeutics Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
Abeona Therapeutics Q2 Results: Revenue Rises 31% QoQ To $11.4 Million - scanx.trade
Abeona Therapeutics (ABEO) Stock Dips After Q2 Miss; Price-to-Sa - GuruFocus
Abeona Therapeutics Q2 2026 Earnings Call Transcript - benzinga.com
Abeona Therapeutics Q2 Earnings Call Highlights - MarketBeat
Abeona stock drops after Q2 revenue miss (ABEO:NASDAQ) - Seeking Alpha
Earnings call transcript: Abeona Therapeutics misses Q2 2026 revenue view as shares fall - Investing.com
Abeona Therapeutics Reports Q2 2026 Results in Form 10-Q Filing - Kalkine Media
Abeona Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Why is Abeona Therapeutics stock slumping today? By Investing.com - Investing.com Canada
Abeona Therapeutics (ABEO) Q2 Earnings Highlight Challenges Amid Soaring Price-to-Sales Ratio - GuruFocus
Is Abeona Therapeutics Inc (ABEO) Facing Sustainability Challeng - GuruFocus
Abeona Therapeutics: Q2 Earnings Snapshot - Yahoo Finance
ABEONA THERAPEUTICS INC. Q2 2026: Revenue $11.38M, EPS $(0.35) — 10-Q Summary - TradingView
Abeona Therapeutics Q2 net loss widens, misses analyst expectations - TradingView
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update - The Manila Times
Abeona Q2 Revenue Rises 31% to $11.4 Million - quiverquant.com
Abeona Therapeutics reports Q2 2026: $11.4M product revenue, $20.2M net loss - TradingView
Abeona Therapeutics (ABEO) grows ZEVASKYN sales but records H1 2026 net loss - Stock Titan
Abeona Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Weekly Recap: CMS NTAP for ZEVASKYN and Q2 2026 results call - TradingView
Abeona will stream its Q2 financial update on Aug. 13 - Stock Titan
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 - GlobeNewswire
Abeona Therapeutics (ABEO) Projected to Announce Earnings on Thursday - MarketBeat
The Technical Signals Behind (ABEO) That Institutions Follow - Stock Traders Daily
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Abeona Therapeutics’ gene therapy receives Medicare payment status - Investing.com
Abeona Therapeutics(R) Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Abeona Therapeutics’ gene therapy receives Medicare payment status By Investing.com - Investing.com South Africa
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN® - The Manila Times
A new CMS payment could help Medicare patients access ZEVASKYN - Stock Titan
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Abeona Therapeutics Inc (ABEO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Abeona Therapeutics Inc (ABEO) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
Law firm probes Abeona Therapeutics for possible director breaches harming shareholders. - Pluang
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO) - PR Newswire
Abeona Therapeutics Inc (ABEO) Dividends & Stock Splits: Historical Payouts and Event Timeline - tradingkey.com
ABEO|Abeona Therapeutics Inc|Price:6.050|Chg%:-0.330 - TradingKey
Abeona Therapeutics Inc (ABEO) Cash Flow - TradingKey
Abeona Therapeutics Inc (ABEO) Balance Sheet - tradingkey.com
Abeona Therapeutics Inc (ABEO) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):